Past Event

2010 Conference on Clinical Cancer Research

On October 20, the Engelberg Center for Health Care Reform and Friends of Cancer Research hosted the 2010 Conference on Clinical Cancer Research, where key stakeholders came together to address specific challenges in clinical cancer research and discuss potential solutions proposed by expert panels.

Panelists and participants represented the range of stakeholders in the cancer community, including senior officials from the U.S. Food and Drug Administration (FDA) and the National Cancer Institute (NCI), as well as thought leaders from academia, patient advocacy organizations, and the life sciences industry. FDA Commissioner Dr. Margaret Hamburg and NCI Director Dr. Harold Varmus offered keynote remarks, and four panel discussions focused on:

  1. Expanding the use of adaptive clinical trial design in oncology;
  2. Innovative and efficient pre-clinical testing;
  3. Incorporating pain metrics into oncology clinical trials; and
  4. Using patient-generated data and samples to develop evidence for targeting approved treaments.

 

Agenda

Welcome

Keynote Address

Panel 1: Expanding the Use of Adaptive Clinical Trial Design in Oncology

A

Raji Sridhara

Acting Director, Division of Biometrics V - U.S. Food and Drug Administration

C

Richard Simon

Chief, Biometric Research Branch, National Cancer Institute

D

Eric Rubin

Deputy Assistant Secretary, European and Eurasian Affairs - U.S. State Department

Panel 2: Innovative and Efficient Pre-Clinical Testing

E

Moderator: Ken Turteltaub

Executive Director, Battelle Center for Fundamental and Applied Systems Technology, Battelle Memorial Institute

A

John Leighton

Associate Director for Pharmacology/Toxicology, U.S. Food and Drug Administration

C

Myrtle Davis

Chief, Toxicology and Pharmacology Branch, National Cancer Institute

D

Adam Clark

Director, Scientific and Federal Affairs, Faster Cures

Lunch and Keynote Remarks

Panel 3: Incorporating Pain Metrics into Oncology Clinical Trials

A

Laurie Burke

Associate Director for Study Endpoints and Labeling Development, Office of New Drugs, U.S. Food and Drug Administration

H

Ann O’Mara

Head of Palliative Care Research, Community Oncology and Prevention Trials Research Group, National Cancer Institute

Panel 4: Patient Generated Samples and Data

D

Ken Buetow

Director, Bioinformatics and Information Technology, National Cancer Institute

Summary and Closing Remarks

More Information

Get a weekly events calendar from Brookings

More